Search

Your search keyword '"Vehling-Kaiser U"' showing total 278 results
Start Over Author "Vehling-Kaiser U"
278 results on '"Vehling-Kaiser U"'

1. Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI

Author

Alig, A.H.S., Modest, D.P., Stintzing, S., Heinrich, K., Geissler, M., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Held, S., Moosmann, N., Stahler, A., Tannapfel, A., Giessen-Jung, C., Jung, A., Weiss, L., and Heinemann, V.

Published
2024
Full Text
View/download PDF

2. Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110)

Author

Boukovala, M., Modest, D.P., Ricard, I., Fischer von Weikersthal, L., Decker, T., Vehling-Kaiser, U., Uhlig, J., Schenk, M., Freiberg-Richter, J., Peuser, B., Denzlinger, C., Peveling Genannt Reddemann, C., Graeven, U., Schuch, G., Schwaner, I., Heinrich, K., Neumann, J., Jung, A., Held, S., Stintzing, S., Heinemann, V., and Michl, M.

Published
2024
Full Text
View/download PDF

5. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Author

Stintzing, S., Miller-Phillips, L., Modest, D.P., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Scheithauer, W., Held, S., Moehler, M., Jagenburg, A., Kirchner, T., Jung, A., and Heinemann, V.

Published
2017
Full Text
View/download PDF

6. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

Author

Hoechstetter, M A, Busch, R, Eichhorst, B, Bühler, A, Winkler, D, Eckart, M J, Vehling-Kaiser, U, Schimke, H, Jäger, U, Hurtz, H J, Hopfinger, G, Hartmann, F, Fuss, H, Abenhardt, W, Blau, I, Freier, W, Müller, L, Goebeler, M, Wendtner, C M, Bahlo, J, Fischer, K, Bentz, M, Emmerich, B, Döhner, H, Hallek, M, and Stilgenbauer, S

Published
2017
Full Text
View/download PDF

7. How can day hospices work - a logic model

Author

Kaiser, F, Vehling-Kaiser, U, Rechenmacher, M, Fiedler, M, Kaiser, U, Kaiser, F, Vehling-Kaiser, U, Rechenmacher, M, Fiedler, M, and Kaiser, U

Published
2023

8. CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

Author

Michl, M., Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmueller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Scheithauer, W., Hielscher, J., Scholz, M., Mueller, S., Lerch, M.M., Modest, D.P., Kirchner, T., Jung, A., and Heinemann, V.

Published
2016
Full Text
View/download PDF

11. 443TiP Impact of a centralized tumour board on secondary intervention rate in patients with RAS mutant metastatic colorectal cancer after first-line treatment with FOLFOXIRI plus bevacizumab (FIRE-7, AIO-KRK-0120)

Author

Stahler, A., primary, Heinrich, K., additional, Stintzing, S., additional, Jelas, I., additional, Pratschke, J., additional, Schöning, W., additional, Angele, M., additional, D'Haese, J., additional, Gebauer, B., additional, Seidensticker, M., additional, Streitparth, F., additional, Kunz, W.G., additional, Corradini, S.D., additional, Stromberger, C., additional, Vehling-Kaiser, U., additional, Zhang, D., additional, Kurreck, A., additional, Alig, A.H.S., additional, Modest, D.P., additional, and Heinemann, V., additional

Published
2022
Full Text
View/download PDF

12. 424P Avelumab added to FOLFIRI plus cetuximab followed by avelumab maintenance in patients with previously untreated RAS wild-type colorectal cancer: The phase-II FIRE-6 (AIO KRK-0118)

Author

Stintzing, S., primary, Dechow, T.N., additional, Vehling-Kaiser, U., additional, Lorenzen, S., additional, Hannig, C-V., additional, Schwaner, I., additional, Fischer von Weikersthal, L., additional, Puchtler, G., additional, Binder, M., additional, Held, S., additional, Heinrich, K., additional, and Heinemann, V., additional

Published
2022
Full Text
View/download PDF

22. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

Author

von Einem, J. C., Heinemann, V., von Weikersthal, L. Fischer, Vehling-Kaiser, U., Stauch, M., Hass, H. G., Decker, T., Klein, S., Held, S., Jung, A., Kirchner, T., Haas, M., Holch, J., Michl, M., Aubele, P., Boeck, S., Schulz, C., Giessen, C., Stintzing, S., and Modest, D. P.

Published
2014
Full Text
View/download PDF

23. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)

Author

Stahler, A., Heinemann, V., Giessen-Jung, C., Crispin, A., Schalhorn, A., Stintzing, S., von Weikersthal, Fischer L., Vehling-Kaiser, U., Stauch, M., Quietzsch, D., Held, S., von Einem, J. C., Holch, J., Neumann, J., Kirchner, T., Jung, A., and Modest, D. P.

Published
2016
Full Text
View/download PDF

24. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAïVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE CLL12 TRIAL.

Author

Langerbeins, P., Robrecht, S., Nieper, P., Cramer, P., Fürstenau, M., Al‐Sawaf, O., Fink, A., Kreuzer, K., Vehling‐Kaiser, U., Tausch, E., Schneider, C., Müller, L., Schlag, R., Freier, W., Gaska, T., Balser, C., Reiser, M., Stauch, M., Zahn, M., and Dörfel, S.

Subjects
CHRONIC lymphocytic leukemia, ASYMPTOMATIC patients, PLACEBOS, RICHTER syndrome
Abstract

B Conclusions: b Early ibrutinib-treatment of patients with asymptomatic Binet stage A CLL at high risk of progression failed to demonstrate an overall survival benefit when compared to placebo. B Introduction: b We present the final analysis of the phase 3, double-blind, placebo-controlled CLL12 trial evaluating ibrutinib in patients with early stage CLL at increased risk of progression defined by a comprehensive score (NCT02863718). [Extracted from the article]

Published
2023
Full Text
View/download PDF

25. PD-027 BRAF mutant and RAS mutant patients treated with FOLFIRI plus Bevacizumab or FOLFIRI plus Cetuximab. Role of ETS and molecular markers in FIRE-3 (AIO KRK-0306)

Author

Stintzing, S., Fischer von Weikersthal, L., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., Kullmann, F., Stauch, M., Hielscher, J., Lerch, M., Scheithauer, W., Jagenburg, A., Held, S., Modest, D., Jung, A., Kirchner, T., and Heinemann, V.

Published
2016
Full Text
View/download PDF

30. Correction:High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Leukemia, (2020), 34, 8, (2074-2086), 10.1038/s41375-020-0826-9)

Author

Hehlmann, Rüdiger, Voskanyan, Astghik, Lauseker, Michael, Pfirrmann, Markus, Kalmanti, Lida, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Haferlach, Claudia, Schlegelberger, Brigitte, Fabarius, Alice, Seifarth, Wolfgang, Spieß, Birgit, Wuchter, Patrick, Krause, Stefan, Kolb, Hans Jochem, Neubauer, Andreas, Hossfeld, Dieter K., Nerl, Christoph, Gratwohl, Alois, Baerlocher, Gabriela M., Burchert, Andreas, Brümmendorf, Tim H., Hasford, Jörg, Hochhaus, Andreas, Saußele, Susanne, Baccarani, Michele, von Weikersthal, L. Fischer, Hahn, M., Schlimok, G., Reichert, D., Janssen, J., Martens, U., Majunke, P., Reichert, Peter, Neben, K., Korsten, S., Scholz, Ch, Oldenkott, B., Heßling, J., Kingreen, D., Sperling, C., Schelenz, C., Blau, I., Urmersbach, A., Ludwig, W., Le Coutre, P., Arnold, R., de Wit, M., Pezzutto, A., Schäfer, E., Schroers, R., Lochter, A., Behringer, D., Ko, Y., Weidenhöfer, S., Verbeek, W., Brossart, P., Trenn, G., Pommerien, W., Krauter, J., Doering, G., Munzinger, H., Diekmann, C., Hertenstein, B., Stier, S., Möller-Faßbender, F., Hänel, M., Zöller, T., Lamberti, C., Koch, B., Henzel, A., Wagner, S., Schmalenbach, A., Hoffknecht, M., Ehninger, G., Kiani, A., Illmer, T., Aul, C., Flaßhove, M., Henneke, F., Simon, M., Müller, L., Becker, H., Janz, R., Eckart, M. J., Fuchs, R., Schlegel, F., Wattad, M., Rudolph, R., Beelen, D. W., Lindemann, A., Linck, D., Wassman, Jäger, E., Al-Batran, S., Reiber, T., Waller, C. F., Hoeffkes, H., Schulz, L., Tajrobehkar, K., Mittermüller, J., Pralle, H., Runde, V., Hoyer, A., Tessen, H., Trümper, L., Schmidt, C., Sieber, M., Eschenburg, H., Depenbusch, R., Rösel, S., Lindemann, H. W., Wolf, H., Spohn, C., Moeller, R., Hossfeld, D., Zander, A., Schafhausen, P., Köster, H., Hollburg, W., Schmitz, N., Dürk, H., Hemeier, M., Grote-Metke, A., Weischer, H., Bechtel, B., Balleisen, L., Sosada, M., Ho, A., Petersen, V., Dengler, J., Bildat, S., Hahn, L., Dietzfelbinger, H., Gröschel, W., Bartholomäus, A., Freier, W., Sievers, B., Pfreundschuh, I. M., Herrmann, T., Fauser, A., Menzel, J., Kemmerling, M., Hansen, R., Link, H., Schatz, M., Bentz, M., Prümmer, O., Kneba, M., Heymanns, J., Schmitz, S., Scheid, C., Lollert, A., Neise, M., Planker, M., Stauch, M., Schröder, M., Kempf, B., Vehling-Kaiser, U., Kremers, S., Köchling, G., Hartmann, F., Neuhaus, T., Fetscher, S., Kämpfe, D., Heil, G., Uppenkamp, M., Goldmann, B., Huber, T. Fischer, Hieber, U., Plöger, C., Griesshammer, M., Lange, C., Göttler, B., Lunscken, C., Schiel, X., Scheidegger, C., Stötzer, O., Hitz, H., Schick, H., Völkl, S., Spiekermann, K., Berdel, W., Hebart, H., Ladda, E., Schmidt, P., Burkhardt, U., Hentschke, S., Falge, C., Reschke, D., Köhne, C. A., Müller-Naendrup, C., Sauer, M., Frühauf, S., Ranft, K., Dencausse, Y., Sandritter, B., Baake, G., Hofknecht, M., Dengler, R., Edinger, M., Schenk, M., Wehmeier, A., Weidelich, H. P., Pihusch, R., Stahlhut, K., Baldus, M., Matzdorff, A., Geer, T., Schanz, S., Käfer, G., Gassmann, W., Priebe-Richter, C., Demandt, M., Springer, G., Fiechtner, H., Denzlinger, C., Schleicher, J., Assman, D., Gaeckler, R., Adam, G., Waladkhani, A., Rendenbach, B., Forstbauer, H., Kanz, L., Jacki, S., Stegelmann, F., Kalhori, N., Nusch, A., Langer, W., Müller, F., Brettner, S., Uebelmesser, B., Kamp, T., Schadeck-Gressel, C., Josten, K., Klein, O., Schwerdtfeger, R., Baurmann, H., Strotkötter, H., Fett, W., Raghavachar, A., Maintz, C., Goebler, M. C., Schlag, R., Elsel, W., Wernli, M., Heim, D., Wuillemin, W., Hess, U., Gmür, J., and Mayer, J.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

31. SO-6 Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group

Author

Weiss, L., Heinemann, V., Fischer, L., Gieseler, F., Hoehler, T., Mayerle, J., Quietzsch, D., Reinacher-Schick, A., Schenk, M., Seipelt, G., Siveke, J., Stahl, M., Vehling-Kaiser, U., Waldschmidt, D., Dorman, K., Zhang, D., Westphalen, B., Haas, M., and Boeck, S.

Published
2023
Full Text
View/download PDF

34. Treatment of Older Patients with Mantle-Cell Lymphoma

Author

Kluin-Nelemans, H. C., Hoster, E., Hermine, O., Walewski, J., Trneny, M., Geisler, C. H., Stilgenbauer, S., Thieblemont, C., Vehling-Kaiser, U., Doorduijn, J. K., Coiffier, B., Forstpointner, R., Tilly, H., Kanz, L., Feugier, P., Szymczyk, M., Hallek, M., Kremers, S., Lepeu, G., Sanhes, L., Zijlstra, J. M., Bouabdallah, R., Lugtenburg, P. J., Macro, M., Pfreundschuh, M., Procházka, V., Di Raimondo, F., Ribrag, V., Uppenkamp, M., André, M., Klapper, W., Hiddemann, W., Unterhalt, M., and Dreyling, M. H.

Published
2012
Full Text
View/download PDF

39. 441P Evaluation of conversion therapy in patients undergoing secondary resection of metastases in curative intent within the FIRE-3 (AIO KRK-0306) study

Author

von Einem, J.C., primary, Heinemann, V., additional, Modest, D.P., additional, Stahler, A., additional, Miller-Phillips, L., additional, Fischer von Weikersthal, L., additional, Decker, T., additional, Kiani, A., additional, Vehling-Kaiser, U., additional, Al-Batran, S-E., additional, Kahl, C., additional, Seipelt, G., additional, Kullmann, F., additional, Scheithauer, W., additional, Jung, A., additional, Kirchner, T., additional, and Stintzing, S., additional

Published
2020
Full Text
View/download PDF

42. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study)

Author

Schmidinger, M. Bamias, A. Procopio, G. Hawkins, R. Sanchez, A.R. Vázquez, S. Srihari, N. Kalofonos, H. Bono, P. Pisal, C.B. Hirschberg, Y. Dezzani, L. Ahmad, Q. Jonasch, E. Gimeno, R.A. Herranz, U.A. Ardavanis, A. Ashraf, S.A. Bamias, A. Barone, C. Bella, S.R. Belz, H. Companario, E.B. Bolling, C. Bono, P. Bothe, K. Carteni, G. Espinosa, J.C. Clausse, M. Confente, C. Coskun, H. Herrero, G.C. Demey, W. D'hondt, R. Santasusana, M.D. Doshi, G. Elkiran, E. Facchini, G. Fein, L. Calvo, O.F. Flaherty, A. Fountzilas, G. Fruehauf, J. Díaz, E.G. Garcia, R. Domínguez, R.G. Ghosn, M. Glorieux, P. Goebell, P.J. Gutierrez, L.G.-A. Gonzalez, M. Green, N.B. Arnau, M.G. Harich, H.-D. Hawkins, R. Hegele, A. Pérez, C.H. Herrmann, E. Horniniger, W.J. Hutson, T.E. Janetschek, G. Kalantari, H. Kalofonos, H. Klausmann, M. Kolin, M. Krause, S. Kroening, H. Sorrosal, J.J.L. Lázaro, M. Lema, M. Lema, M.L. Lin, J. Lueck, A. Lybaert, W. Magi, A. Marina, V.A. Rey, J.P.M. Matus, G. Melear, J. Gonzalez, B.M. Milella, M. Montalar, J. Ferrandis, J.M. Nathan, P. Nechushtan, H. Nusch, A. Ojamaa, K. Oksuzoglu, B. Ozkan, M. Papazisis, K. Passalacqua, R. Pe'er, A. Gracia, J.L.P. Pichler, A. Pokker, H. Porta, C. Rauchenwald, M. Richardet, M.E. Richey, S.L. Garcia, J.M.R. Sánchez, A.R. Rudolph, R. Sabbatini, R. Salmon, J.-P. Lobera, C.S. Sarid, D.L. Saylors, G.B. Schmidinger, M. Schrijvers, D. Schulze, M. Sevilay, A. Shumaker, G.G. Siemer, S. de Prado y Otero, D.S. Srihari, N. Stoiber, F. Rodriguez, C.S. Varela, M.S. Vasanthan, S. Estevez, S.V. Vehling-Kaiser, U. Vogelzang, N. Weiss, H. Whenham, N. Wyendaele, W. Yildiz, R. Yucel, I. Zarba, J.J. Zarkar, A. Zhong, W. Ziem, P. the PRINCIPAL Study Group

Abstract

Background: Real-world data are essential to accurately assessing efficacy and toxicity of approved agents in everyday practice. PRINCIPAL, a prospective, observational study, was designed to confirm the real-world safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC). Subjects, Materials, and Methods: Patients with clear cell advanced/metastatic RCC and a clinical decision to initiate pazopanib treatment within 30 days of enrollment were eligible. Primary objectives included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), relative dose intensity (RDI) and its effect on treatment outcomes, change in health-related quality of life (HRQoL), and safety. We also compared characteristics and outcomes of clinical-trial-eligible (CTE) patients, defined using COMPARZ trial eligibility criteria, with those of non-clinical-trial-eligible (NCTE) patients. Secondary study objectives were to evaluate clinical efficacy, safety, and RDI in patient subgroups. Results: Six hundred fifty-seven patients were enrolled and received ≥1 dose of pazopanib. Median PFS and OS were 10.3 months (95% confidence interval [CI], 9.2–12.0) and 29.9 months (95% CI, 24.7 to not reached), respectively, and the ORR was 30.3%. HRQoL showed no or little deterioration over time. Treatment-related serious adverse events (AEs) and AEs of special interest occurred in 64 (9.7%), and 399 (60.7%) patients, respectively. More patients were classified NCTE than CTE (85.2% vs. 14.8%). Efficacy of pazopanib was similar between the two groups. Conclusion: PRINCIPAL confirms the efficacy and safety of pazopanib in patients with advanced/metastatic RCC in a real-world clinical setting. Implications for Practice: PRINCIPAL is the largest (n = 657) prospective, observational study of pazopanib in patients with advanced/metastatic renal cell carcinoma, to the authors’ knowledge. Consistent with clinical trial results that often contain specific patient types, the PRINCIPAL study demonstrated that the effectiveness and safety of pazopanib is similarly safe and effective in patients with advanced kidney cancer in a real-world clinical setting. The PRINCIPAL study showed that patients with advanced kidney cancer who are treated with first-line pazopanib generally do not show disease progression for approximately 10 months and generally survive for nearly 30 months. © AlphaMed Press 2019

Published
2019

43. Identification and Combination of Independent Established (Thymidine Kinase, Lymphocyte Doubling Time) and Modern Prognostic Parameters (Genetic Aberrations IgVH Mutational Status) helps to Predict Individual Risk for Rapid Disease Progression in Patients with B-CLL in Stage Binet A: Report of the CLL1 Protocol of the German CLL Study Group: O141

Author

Bergmann, M., Eichhorst, B., Busch, R., Stilgenbauer, S., Kröber, A., Döhner, H., Adorf, A., Eckhardt, M., Vehling-Kaiser, U., Bosse, D., Schimke, H., Emmerich, B., and Hallek, M.

Published
2004

49. IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL

Author

Langerbeins, P., primary, Bahlo, J., additional, Rhein, C., additional, Gerwin, H., additional, Cramer, P., additional, Fürstenau, M., additional, Al-Sawaf, O., additional, von Tresckow, J., additional, Fink, A.M., additional, Kreuzer, K., additional, Vehling-Kaiser, U., additional, Tausch, E., additional, Müller, L., additional, Eckart, M., additional, Schlag, R., additional, Freier, W., additional, Gaska, T., additional, Balser, C., additional, Reiser, M., additional, Stauch, M., additional, Wendtner, C., additional, Fischer, K., additional, Stilgenbauer, S., additional, Eichhorst, B., additional, and Hallek, M., additional

Published
2019
Full Text
View/download PDF

50. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

Author

Holch, J.W., primary, Ricard, I., additional, Stintzing, S., additional, Fischer von Weikersthal, L., additional, Decker, T., additional, Kiani, A., additional, Vehling-Kaiser, U., additional, Heintges, T., additional, Kahl, C., additional, Kullmann, F., additional, Scheithauer, W., additional, Moehler, M., additional, Jelas, I., additional, Modest, D.P., additional, Westphalen, C.B., additional, von Einem, J.C., additional, Michl, M., additional, and Heinemann, V., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results